Vincent, Catherine

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: Interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Younossi, Z. M., Ratziu, V., Loomba, R., Rinella, M., Anstee, Q. M., Goodman, Z., Bedossa, P., Geier, A., Beckebaum, S., Newsome, P. N., et al. (2019) · The Lancet

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 1,277

A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis

Nevens, F., Andreone, P., Mazzella, G., Strasser, S. I., Bowlus, C., Invernizzi, P., Drenth, J. P. H., Pockros, P. J., Regula, J., Beuers, U., et al. (2016) · New England Journal of Medicine

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 1,131

Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid

Hirschfield, G. M., Mason, A., Luketic, V., Lindor, K., Gordon, S. C., Mayo, M., Kowdley, K. V., Vincent, C., Bodhenheimer, H. C., Parés, A., et al. (2015) · Gastroenterology

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 576

International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways

Cordell, H. J., Han, Y., Mells, G. F., Li, Y., Hirschfield, G. M., Greene, C. S., Xie, G., Juran, B. D., Zhu, D., Qian, D. C., et al. (2015) · Nature Communications

Liver Diseases and ImmunityGenetic Associations and Epidemiology

Cited by 287

A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis

Kowdley, K. V., Luketic, V., Chapman, R., Hirschfield, G. M., Poupon, R., Schramm, C., Vincent, C., Rust, C., Parés, A., Mason, A., et al. (2018) · Hepatology

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 281

Variants at IRF5-TNPO3, 17q12-21 and MMEL1 are associated with primary biliary cirrhosis

Hirschfield, G. M., Liu, X., Han, Y., Gorlov, I. P., Lu, Y., Xu, C., Lu, Y., Chen, W., Juran, B. D., Coltescu, C., et al. (2010) · Nature Genetics

Liver Diseases and ImmunityGenetic Associations and Epidemiology

Cited by 215

An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs

Cordell, H. J., Fryett, J. J., Ueno, K., Darlay, R., Aiba, Y., Hitomi, Y., Kawashima, M., Nishida, N., Khor, S.-S., Gervais, O., et al. (2021) · Journal of Hepatology

Liver Diseases and ImmunityGenetic Associations and Epidemiology

Cited by 182

Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants

Juran, B. D., Hirschfield, G. M., Invernizzi, P., Atkinson, E. J., Li, Y., Xie, G., Kosoy, R., Ransom, M., Sun, Y., Bianchi, I., et al. (2012) · Human Molecular Genetics

Liver Diseases and ImmunityGenetic Associations and Epidemiology

Cited by 150

Association of primary biliary cirrhosis with variants in the CLEC16A, SOCS1, SPIB and SIAE immunomodulatory genes

Hirschfield, G. M., Xie, G., Lu, E., Sun, Y., Juran, B. D., Chellappa, V, Coltescu, C., Mason, A. L., Milkiewicz, P., Myers, R. P., et al. (2012) · Genes & Immunity

Liver Diseases and ImmunityGenetic Associations and Epidemiology

Cited by 85

Portal hypertension and primary biliary cirrhosis: effect of long-term ursodeoxycholic acid treatment

Huet, P., Vincent, C., Deslaurier, J., Coté, J., Matsutami, S., Boileau, R., & Huet–van Kerckvoorde, J. (2008) · Gastroenterology

Liver Diseases and ImmunityLiver Disease and Transplantation

Cited by 84

Real‐World Effectiveness of Obeticholic Acid in Patients with Primary Biliary Cholangitis

Roberts, S. B., Ismail, M., Kanagalingam, G., Mason, A. L., Swain, M. G., Vincent, C., Yoshida, E. M., Tsien, C., Flemming, J. A., Janssen, H. L. A., et al. (2020) · Hepatology Communications

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 58

964 THE FARNESOID X RECEPTOR (FXR) AGONIST OBETICHOLIC ACID (OCA) INCREASES PLASMA FGF-19 CONCENTRATIONS AND DECREASES BILE ACID SYNTHESIS IN PRIMARY BILIARY CIRRHOSIS (PBC)

Marschall, H.-U., Luketic, V., Lovgren-Sandblom, A., Benthin, L., Kowdley, K., Hirschfield, G., Mason, A., Lindor, K., Gordon, S., Vincent, C., et al. (2012) · Journal of Hepatology

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 9